

Angel Perez-Sempere

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2488276/publications.pdf>

Version: 2024-02-01

70
papers

1,364
citations

304368

22
h-index

377514

34
g-index

70
all docs

70
docs citations

70
times ranked

1700
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroimaging in the Evaluation of Patients with Non-Acute Headache. <i>Cephalalgia</i> , 2005, 25, 30-35.	1.8	110
2	Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivity. <i>Movement Disorders</i> , 1995, 10, 643-649.	2.2	74
3	Prevalence of Parkinson's disease in Cantalejo, Spain: A door-to-door survey. <i>Movement Disorders</i> , 2002, 17, 242-249.	2.2	68
4	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1303-1310.	1.4	57
5	First seizure in adults: a prospective study from the emergency department. <i>Acta Neurologica Scandinavica</i> , 1992, 86, 134-138.	1.0	52
6	Switching from natalizumab to fingolimod: an observational study. <i>Acta Neurologica Scandinavica</i> , 2013, 128, e6-e10.	1.0	52
7	Rebound of disease activity during pregnancy after withdrawal of fingolimod. <i>European Journal of Neurology</i> , 2013, 20, e109-10.	1.7	52
8	Acute Headache of Recent Onset and Subarachnoid Hemorrhage: A Prospective Study. <i>Headache</i> , 1994, 34, 172-174.	1.8	45
9	Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DISCUTIR MS). <i>Frontiers in Neurology</i> , 2017, 8, 65.	1.1	42
10	Incidence of Transient Ischemic Attacks and Minor Ischemic Strokes in Segovia, Spain. <i>Stroke</i> , 1996, 27, 667-671.	1.0	42
11	Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DISCUTIR MS). <i>BMC Neurology</i> , 2016, 16, 58.	0.8	41
12	Spongiform leucoencephalopathy after inhaling heroin. <i>Lancet, The</i> , 1991, 338, 320.	6.3	35
13	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 742-748.	1.4	35
14	Cerebral Ischemia: New Risk Factors. <i>Cerebrovascular Diseases</i> , 2004, 17, 43-50.	0.8	32
15	Headache of recent onset in adults: a prospective population-based study. <i>Acta Neurologica Scandinavica</i> , 1996, 94, 67-70.	1.0	29
16	Mutation Prevalence of Cerebral Cavernous Malformation Genes in Spanish Patients. <i>PLoS ONE</i> , 2014, 9, e86286.	1.1	29
17	Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. <i>BMJ Open</i> , 2017, 7, e014433.	0.8	28
18	Parkinsonism induced by amlodipine. <i>Movement Disorders</i> , 1995, 10, 115-116.	2.2	27

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Infection in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	27
20	Response to Immunotherapy in CLIPPERS: Clinical, MRI, and MRS Follow-up. <i>Journal of Neuroimaging</i> , 2013, 23, 254-255.	1.0	26
21	Aggravation of Parkinsonian Tremor by Cisapride. <i>Clinical Neuropharmacology</i> , 1995, 18, 76-78.	0.2	24
22	Etiopathogenesis of Transient Ischemic Attacks and Minor Ischemic Strokes. <i>Stroke</i> , 1998, 29, 40-45.	1.0	24
23	Bibliometric profile of the global scientific research on multiple sclerosis (2003-2012). <i>Multiple Sclerosis Journal</i> , 2015, 21, 235-245.	1.4	24
24	Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 385-394.	1.7	23
25	Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin. <i>Journal of Neurology</i> , 1995, 242, 114-115.	1.8	19
26	Primary Cough Headache Responsive to Topiramate. <i>Cephalalgia</i> , 2005, 25, 627-628.	1.8	18
27	Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese Data. <i>Neuroepidemiology</i> , 2012, 38, 209-216.	1.1	18
28	Postural Myoclonus Induced by Phenytoin. <i>Clinical Neuropharmacology</i> , 1996, 19, 536-538.	0.2	17
29	Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. <i>Journal of Neurology</i> , 2019, 266, 2512-2517.	1.8	17
30	Clinical characteristics associated with psychosocial functioning among patients with uncomplicated epilepsy in Spain. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2007, 16, 195-203.	0.9	16
31	Rescue Therapy Using Rituximab for Multiple Sclerosis. <i>Clinical Neuropharmacology</i> , 2016, 39, 178-181.	0.2	16
32	Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. <i>Frontiers in Neurology</i> , 2017, 8, 430.	1.1	16
33	Parkinsonism and tardive dyskinesia after chronic use of clebopride. <i>Movement Disorders</i> , 1994, 9, 114-115.	2.2	14
34	Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1338-1339.	0.9	14
35	Pseudopheochromocytoma in a Patient with Parkinson's Disease. <i>Annals of Pharmacotherapy</i> , 1996, 30, 546-546.	0.9	13
36	Observational Study of Switching from Natalizumab to Immunomodulatory Drugs. <i>European Neurology</i> , 2017, 77, 130-136.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Isolated Oculomotor Nerve Palsy due to Dural Cavernous Sinus Fistula. <i>European Neurology</i> , 1991, 31, 186-187.	0.6	12
38	Low-Dose Sodium Valproate in the Prophylaxis of Migraine. <i>Clinical Neuropharmacology</i> , 1994, 17, 569-573.	0.2	12
39	Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DISCUTIR MS. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 175-180.	0.8	11
40	Guillain-Barré Syndrome After Acute Myocardial Infarction Treated With Anistreplase. <i>Chest</i> , 1994, 105, 1301-1302.	0.4	10
41	Bilateral optic neuritis in a 26-year-old man with common variable immunodeficiency: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 319.	0.4	9
42	Benign hereditary chorea: Clinical features and long-term follow-up in a Spanish family. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 394-396.	1.1	9
43	Eyelid myokymia in patients with migraine taking topiramate. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 143-146.	1.0	9
44	Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective. <i>Neurology and Therapy</i> , 2020, 9, 173-179.	1.4	9
45	Reversible Dementia Secondary to Topiramate. <i>Clinical Neuropharmacology</i> , 2008, 31, 62.	0.2	8
46	Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 78-81.	0.9	8
47	Understanding the Deterioration of Gait, Postural Control, Lower Limb Strength and Perceived Fatigue Across the Disability Spectrum of People with Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1385.	1.0	7
48	Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1287-1289.	1.0	6
49	Intravenous Midazolam Suppression of Complex Partial Status Refractory to Intravenous Phenytoin and Diazepam. <i>Clinical Neuropharmacology</i> , 1993, 16, 468-470.	0.2	5
50	Linfoma cerebral primario con remisión espontánea. <i>Neurología</i> , 2013, 28, 123-126.	0.3	5
51	Folletos de información educativa en migraña: satisfacción percibida en un grupo de pacientes. <i>Neurología</i> , 2015, 30, 472-478.	0.3	5
52	Contribution of Gray Matter Atrophy and White Matter Damage to Cognitive Impairment in Mildly Disabled Relapsing-Remitting Multiple Sclerosis Patients. <i>Diagnostics</i> , 2021, 11, 578.	1.3	5
53	Regret and Therapeutic Decisions in Multiple Sclerosis Care: Literature Review and Research Protocol. <i>Frontiers in Neurology</i> , 2021, 12, 675520.	1.1	5
54	Bilateral akinetic seizures: A clinical and electroencephalographic description. <i>Epilepsia</i> , 2010, 51, 2108-2115.	2.6	4

#	ARTICLE	IF	CITATIONS
55	Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102354.	0.9	4
56	Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. <i>PLoS ONE</i> , 2021, 16, e0261050.	1.1	4
57	Serum levels of nitrates in focal cerebral ischemia. <i>European Journal of Neurology</i> , 1995, 2, 225-227.	1.7	3
58	Generalized spike-and-wave patterns in children: clinical correlates. <i>Pediatric Neurology</i> , 2000, 22, 23-28.	1.0	3
59	Oral BG-12 in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2013, 368, 1652-1653.	13.9	3
60	Does attendance at theECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731983522.	0.5	3
61	Cerebral venous thrombosis as a cause of neonatal focal clonic seizures. <i>Journal of Neurology</i> , 1992, 239, 294-294.	1.8	3
62	Impotence Associated with Cinnarizine. <i>Annals of Pharmacotherapy</i> , 1993, 27, 370-371.	0.9	2
63	Peripheral iron metabolism in patients with focal cerebral ischemia. <i>European Journal of Neurology</i> , 1995, 2, 107-109.	1.7	2
64	Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. <i>European Journal of Neurology</i> , 1996, 3, 397-398.	1.7	2
65	A general presentation on how to carry out a <sc>CHARMS</sc> analysis for prognostic multivariate models. <i>Statistics in Medicine</i> , 2020, 39, 3207-3225.	0.8	2
66	High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions. <i>Patient</i> , 2021, 14, 241-248.	1.1	2
67	Thyroxine-Induced Partial Complex Status Epilepticus. <i>Annals of Pharmacotherapy</i> , 1993, 27, 1139-1139.	0.9	1
68	Efficacy of Intranasal Apomorphine in Parkinson's Disease. <i>Journal of Pharmacy Technology</i> , 1995, 11, 226-228.	0.5	1
69	Adaptaci3n cultural y validaci3n al espa3ol de Espa3a del MSTCQ4 (Multiple Sclerosis Treatment) Tj ETQq1 1 0.784314 rgBT /Ov	0.3	1
70	Non-ischaeamic causes of transient ischaemic attacks and minor strokes.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 659-660.	0.9	0